Personalized medicine

  • DATABASE (52)

  • ARTICLES (97)

    • DATABASE (52)
    • ARTICLES (97)
  • Sort by
    • Relevance
    • Date

Impress raised €50m Series A funding in May 2021 for its invisible, self-removable teeth aligners, state-of-the-art clinics and hybrid in-person visits and remote monitoring.

Virtual clinic using statistical learning models at the forefront of digital epidemiology to prevent respiratory diseases with 95% accuracy.

Pioneering SaaS with AI-refined content keeps healthcare workers up-to-date on the latest treatments, including clinical simulations with tests and research personalized to users.  

Triporate's AI-powered personal corporate travel planner lets you bypass travel agents for a fully streamlined online experience.   

Pioneering AI SaaS combining virtual clinic and database for mental health professionals enables quicker diagnoses, with up to 90% accuracy.

Ecertic's EADTrust-approved digital identity solutions ensure companies who digitize their business processes also adhere to the latest local regulations. 

Bristol Myers Squibb or BMS is one of the world’s largest biopharmaceutical companies developing medicines in oncology, hematology, immunology and cardiovascular disease. It invests directly and via VC funds, including Life Sciences Partners (LSP) and BioGeneration Ventures, as LP. BMS is headquartered in New York and has 10 offices and facilities within the US and 13 in overseas locations, namely, Puerto Rico, Canada, France, Belgium, the UK, Ireland, Germany, Japan and China. 

Sorry, we couldn’t find any matches for “Personalized medicine”.

Your payment was not successful.

Please make sure you have entered your payment details correctly. Or try again in a few moments.

small logo

The discount code you entered is invalid

Please make sure you have entered your discount code correctly. Or try again in a few moments.

Download successful.

Your sample has been sent. Please check your email.

By accessing and using www.compasslist.com and all pages within the domain (the “Website”), You accept and agree to have read, understood, accepted and agreed to be bound by the Terms of Use and Privacy Policy in full. If you disagree with all or any part of these Terms of Use and Privacy Policy, please do not use or continue any further use of this website. You acknowledge that you are aware that this Website contains an archive of existing content as at 31 December 2021 and is not being actively managed. We are under no obligation to update the content on this Website and, accordingly, no new content or articles will be posted to the Website after 31 December 2021.